Dermatomyositis and Polymyositis Registry (ADAPT)

This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
Phoenix Neurological Associates, LTD Identifier:
First received: July 6, 2012
Last updated: November 5, 2015
Last verified: November 2015
By creating a registry, physicians will have the opportunity to understand the clinical outcomes of Myositis patients treated with Acthar. Despite the availability of clinical exams, muscle biopsies, and other testing, it is surmised that there may be a more important classification of myositis that physicians are not diagnosing which could possibly lead to improper treatment due to inaccurate diagnosis. There may be several types of immune and inflammatory myositis (IIM) that do not fit well into the typical sub classifications of myositis.

Condition Intervention
Drug: Acthar

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Acthar Dermatomyositis and Polymyositis Treatment

Resource links provided by NLM:

Further study details as provided by Phoenix Neurological Associates, LTD:

Primary Outcome Measures:
  • Determining if Acthar treatment improves disease progression [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To create and maintain a registry linking clinical information, dosing and clinical response in patients with refractory myositis and to determine if Acthar treatment improves disease progression

Secondary Outcome Measures:
  • Subgroups may predict response to Acthar therapy [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine if there are different subgroups that can be defined myopathologically that may predict response to Acthar therapy.

Biospecimen Retention:   None Retained
This is a retrospective and prospective study

Estimated Enrollment: 100
Study Start Date: April 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Acthar
    Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
    Other Name: ACTH
Detailed Description:
Retrospective and prospective data will be collected from physicians who have prescribed Acthar to myositis patients to determine what specific characteristics each patient has based on biopsy analysis, laboratory results, and clinical exams. Through biopsy analysis, subcategories of IIM will be determined and could illustrate which of these IIMs may be more responsive to Acthar therapy.

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All sites chosen are well-established universities, academic centers or private practices that specialize in neuromuscular diseases. These are physicians who have several myositis patients and who are prescribing or would prescribe Acthar to myositis patients

Inclusion Criteria:

  1. Age 18-85
  2. Male or Female
  3. Clinical or pathologic diagnosis of polymyositis or dermatomyositis
  4. Capable of providing informed consent and complying with treatment regimen

Exclusion Criteria:

  1. History of scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex
  2. Recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, or sensitivity to proteins of porcine origin
  3. Any other co-morbid condition which would make completion of the trial unlikely
  4. If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness to use appropriate birth control
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01637064

United States, Arizona
PNA Center for Neurological Research
Phoenix, Arizona, United States, 85018
United States, California
Ara Dikranian MD
San Diego, California, United States, 92108
United States, Missouri
Neurology INC
Columbia, Missouri, United States, 65201
United States, New York
New York Methodist Hospital
Brooklyn, New York, United States, 11215
United States, Vermont
University of Vermont
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
Phoenix Neurological Associates, LTD
Principal Investigator: Todd D Levine, MD Phoenix Neurological Associates, LTD
Principal Investigator: Petros Efthimiou, MD New York Methodist Hospital
Principal Investigator: Ara Dikranian, MD Ara Dikranian MD
Principal Investigator: Justine Malone, MD Neurology INC
Principal Investigator: Rup Tandan, MD University of Vermont
  More Information

No publications provided

Responsible Party: Phoenix Neurological Associates, LTD Identifier: NCT01637064     History of Changes
Other Study ID Numbers: ADAPT
Study First Received: July 6, 2012
Last Updated: November 5, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Phoenix Neurological Associates, LTD:
Acthar treatment

Additional relevant MeSH terms:
Connective Tissue Diseases
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Skin Diseases processed this record on November 24, 2015